| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.091 | 0.09 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.09 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.09 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.076 | 0.09 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.079 | 0.09 |